Joinn Laboratories (China) Co Ltd
Company Profile
Business description
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non-Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Contact
A5 Rongjing East Street
Beijing Economic-Technological Development Area
Beijing100176
CHNT: +86 1067869966
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
2,652
Stocks News & Analysis
stocks
Earnings up but shares overvalued for ASX gold miner
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,362.70 | 5.90 | 0.06% |
| CAC 40 | 8,225.63 | 0.15 | -0.00% |
| DAX 40 | 24,239.89 | 32.10 | 0.13% |
| Dow JONES (US) | 47,207.12 | 472.51 | 1.01% |
| FTSE 100 | 9,645.62 | 67.05 | 0.70% |
| HKSE | 26,425.60 | 265.45 | 1.01% |
| NASDAQ | 23,204.87 | 263.07 | 1.15% |
| Nikkei 225 | 50,417.63 | 1,117.98 | 2.27% |
| NZX 50 Index | 13,391.59 | 14.49 | 0.11% |
| S&P 500 | 6,791.69 | 53.25 | 0.79% |
| S&P/ASX 200 | 9,064.50 | 6.70 | 0.07% |
| SSE Composite Index | 3,980.82 | 30.50 | 0.77% |